Both ingredients offer increased bioavailability, compared with the standard form of the ingredient, said the companies. Theracurmin has been shown to be 27 times more bioavailable than standard curcumin powder in human clinical studies, while human clinicals have also shown enzymatically-modified isoquercitrin (EMIQ) to be 17 times more bioavailable than quercetin.
“We developed patented technologies to make highly bioavailable Theracurmin and EMIQ, increasing bioavailability for more efficient dosages then invested in successful human clinical trials,” said Tadashi Hashimoto, Representative Director and President of Theravalues Corporation.
“I am confident and enthusiastic that this strategic partnership with Innophos Nutrition will accelerate the expansion of these fantastic ingredients and consequently, improve health and wellness of people in the USA.”
According to the terms of the agreement, Innophos Nutrition will employ its sales, marketing, and distribution expertise and leverage its relationships with finished product manufacturers, to present and distribute Theracurmin and EMIQ.
“We are excited about the addition of Theracurmin and EMIQ into our signature ingredient portfolio,” said Bruce Brown, Vice President, Innophos Nutrition. “Theracurmin is the most clinically studied and versatile curcumin product on the market. EMIQ is a unique, water-soluble and highly active polyphenol. Both Theracurmin and EMIQ deliver superior health benefits and extensive formulation opportunities.”
Theracurmin is a water dispersible, heat and light stable, ingredient that can be used in a variety of delivery forms, said Innophos. The ingredient has been used in 19 completed human clinical trials and 15 ongoing studies to continue to show its benefits on human health, according to the company.
EMIQ is a water-soluble polyphenol derived from rutin, explained Innophos. Data from human clinical trials indicated that EMIQ increases markers of body fat metabolism and is a powerful antioxidant that supports the immune system and cellular health, said the company.